About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Zydus Lifesciences Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
29-Jan-2024
09-Feb-2024
Quarterly Results & Buy Back of Shares
30-Oct-2023
07-Nov-2023
Quarterly Results
31-Jul-2023
11-Aug-2023
Quarterly Results
12-May-2023
18-May-2023
Final Dividend & Audited Results
23-Jan-2023
03-Feb-2023
Quarterly Results
31-Oct-2022
11-Nov-2022
Quarterly Results
03-Aug-2022
10-Aug-2022
Quarterly Results
13-May-2022
20-May-2022
Final Dividend & Audited Results
25-Jan-2022
03-Feb-2022
Quarterly Results
20-Oct-2021
29-Oct-2021
Quarterly Results
03-Aug-2021
11-Aug-2021
Quarterly Results
21-May-2021
27-May-2021
Final Dividend & Audited Results
27-Jan-2021
05-Feb-2021
Quarterly Results
20-Oct-2020
02-Nov-2020
Quarterly Results
27-Jul-2020
05-Aug-2020
Quarterly Results
15-Jun-2020
19-Jun-2020
Audited Results
11-Mar-2020
16-Mar-2020
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2020 ,inter alia, to consider and approve Interim Dividend 2019-2020
17-Jan-2020
05-Feb-2020
Quarterly Results
18-Oct-2019
13-Nov-2019
Quarterly Results
16-Jul-2019
09-Aug-2019
Quarterly Results
Page
1
of
6
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Awareness & Information
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.